Breckenridge Pharmaceutical announced a strategic collaboration with Medichem Solutions encompassing a range of injectable products used across therapeutic areas such as anesthesia, critical care, and emergency medicine. The collaboration expands Breckenridge's injectable business line and strengthens its ongoing commitment to the U.S. hospital channel, while reinforcing its long-term focus on delivering high-quality, affordable medicines upon which clinicians depend to treat patients. The collaboration reflects a dedication shared by both Breckenridge and Medichem Solutions to quality and reliability, and to addressing critical patient needs across hospital settings.
"This collaboration strengthens Breckenridge's growing presence in the hospital channel and represents another important milestone in our strategic evolution into three distinct, patient-focused business lines: specialty, hospital, and retail," said Brian Guy, President and Chief Commercial Officer of Breckenridge. "By partnering with Medichem Solutions, a trusted and experienced organization, we continue to build a diversified, patient-focused portfolio that supports healthcare providers with reliable, cost-effective treatment options."
"Medichem Solutions is very excited to partner with Breckenridge on some of the first products to be manufactured at our new, state-of-the-art facility in Asturias, Spain. This site adds sterile fill-and-finish capabilities to Medichem's B2B platform and reinforces our purpose of supporting partners in expanding their portfolios of affordable, high-quality medicines," said Olga Urazova, Chief Commercial Officer of Medichem.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!